Cytokeratin-19 and Mammaglobin Gene Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients Enrolled in North Central Cancer Treatment Group Trials, N0234/336/436/437

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2011 Oct 7

PMID 21976532

Citations 28

Authors

Monica M Reinholz

Kathleen A Kitzmann

Kathleen Tenner

David Hillman

Amylou C Dueck

Timothy J Hobday

Donald W Northfelt

Alvaro Moreno-Aspitia

Vivek Roy

Betsy Laplant

Jake B Allred

Philip J Stella

Wilma L Lingle

Edith A Perez

Affiliations

Soon will be listed here.

Abstract

Purpose: To investigate the associations between baseline and posttreatment circulating tumor cell (CTC) gene expression and outcome of patients enrolled in four North Central Cancer Treatment Group metastatic breast cancer (MBC) trials in which specimens were shipped (at 4°C) from community-based sites to a reference laboratory (Mayo Clinic, Rochester, MN).

Experimental Design: Blood was collected at treating sites from MBC patients before (baseline), during, and at the end of treatment with erlotinib + gemcitabine (N0234), sorafenib (N0336), irinotecan + cetuximab (N0436), or paclitaxel-poliglumex + capecitabine (N0437). CTCs from 10 mL of EDTA blood were enriched with CD45 depletion, 24 to 30 hours postblood collection. Reverse transcription/quantitative PCR was used to determine cytokeratin-19 (CK19) and mammaglobin (MGB1) mRNA levels in CTCs from up to 13 (N0234), 16 (N0336), 18 (N0436), and 39 (N0437) patients. The gene expressions were normalized to β(2)-microglobulin and calibrated to healthy blood using the 2(-ΔΔCq) algorithm; positivity was defined as 2 or more.

Results: CK19+mRNA cells were detected in 56% to 75% and MGB1+mRNA cells in 23% to 38% of 86 patients at baseline. CK19+mRNA cells were detected in 30% to 67% and MGB1+mRNA cells in 14% to 64% of 110 postbaseline serial samples. The presence of baseline CK19+mRNA cells (P = 0.01) but not MGB1+mRNA cells (P = 0.14) was significantly associated with shorter overall survival. A decrease in MGB1+mRNA levels (baseline-week 8) seemed to be associated with clinical response (P = 0.05).

Conclusions: CTC gene expression analysis conducted by a reference laboratory is feasible when blood is collected from treating sites and processed 24 to 30 hours postcollection. The presence of baseline CK19+mRNA CTCs was associated with poor prognosis; a decrease in MGB1+mRNA CTCs may help predict response to therapy of MBC patients.

Citing Articles

Identification and validation the predictive biomarkers based on risk-adjusted control chart in gemcitabine with or without erlotinib for pancreatic cancer therapy.

Zhao A, Tu D, He Y, Liu L, Wu B, Ren Y Front Genet. 2025; 15:1497254.

PMID: 39741907 PMC: 11685217. DOI: 10.3389/fgene.2024.1497254.

Role of Circulating Tumor Cells in Determining Prognosis in Metastatic Breast Cancer.

Dhaka S, Tripathi R, Chandra Doval D, Mehta A, Maheshwari U, Koyyala V South Asian J Cancer. 2023; 12(1):62-67.

PMID: 36851934 PMC: 9966169. DOI: 10.1055/s-0042-1753477.

Alterations of Cytoskeleton Networks in Cell Fate Determination and Cancer Development.

Wang E, Chen I, Kuo B, Yu C, Lai M, Lin J Biomolecules. 2022; 12(12).

PMID: 36551290 PMC: 9775460. DOI: 10.3390/biom12121862.

Strategies for enrichment of circulating tumor cells.

Li X, Li Y, Shao W, Li Z, Zhao R, Ye Z Transl Cancer Res. 2022; 9(3):2012-2025.

PMID: 35117548 PMC: 8797280. DOI: 10.21037/tcr.2020.01.17.

Circulating Tumor Cells Expressing Krüppel-Like Factor 8 and Vimentin as Predictors of Poor Prognosis in Pancreatic Cancer Patients.

Zhu P, Liu H, Liu F, Gu F, Yuan S, Huang J Cancer Control. 2021; 28:10732748211027163.

PMID: 34378430 PMC: 8361509. DOI: 10.1177/10732748211027163.

References

Nunez-Villar M, Martinez-Arribas F, Pollan M, Lucas A, Sanchez J, Tejerina A . Elevated mammaglobin (h-MAM) expression in breast cancer is associated with clinical and biological features defining a less aggressive tumour phenotype. Breast Cancer Res. 2003; 5(3):R65-70. PMC: 165002. DOI: 10.1186/bcr587. View

Ring A, Smith I, Dowsett M . Circulating tumour cells in breast cancer. Lancet Oncol. 2004; 5(2):79-88. DOI: 10.1016/S1470-2045(04)01381-6. View

Shen C, Hu L, Xia L, Li Y . The detection of circulating tumor cells of breast cancer patients by using multimarker (Survivin, hTERT and hMAM) quantitative real-time PCR. Clin Biochem. 2008; 42(3):194-200. DOI: 10.1016/j.clinbiochem.2008.10.016. View

Fehm T, Braun S, Muller V, Janni W, Gebauer G, Marth C . A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer. 2006; 107(5):885-92. DOI: 10.1002/cncr.22076. View

Hayes D, Cristofanilli M, Budd G, Ellis M, Stopeck A, Miller M . Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006; 12(14 Pt 1):4218-24. DOI: 10.1158/1078-0432.CCR-05-2821. View

Lang J, Mosalpuria K, Cristofanilli M, Krishnamurthy S, Reuben J, Singh B . HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast Cancer Res Treat. 2008; 113(3):501-7. PMC: 5847290. DOI: 10.1007/s10549-008-9951-2. View

Pfaffl M . A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001; 29(9):e45. PMC: 55695. DOI: 10.1093/nar/29.9.e45. View

Hauch S, Zimmermann S, Lankiewicz S, Zieglschmid V, Bocher O, Albert W . The clinical significance of circulating tumour cells in breast cancer and colorectal cancer patients. Anticancer Res. 2007; 27(3A):1337-41. View

Giribaldi G, Procida S, Ulliers D, Mannu F, Volpatto R, Mandili G . Specific detection of cytokeratin 20-positive cells in blood of colorectal and breast cancer patients by a high sensitivity real-time reverse transcriptase-polymerase chain reaction method. J Mol Diagn. 2006; 8(1):105-12. PMC: 1867572. DOI: 10.2353/jmoldx.2006.050054. View

10.

Bitisik O, Saip P, Saglam S, Derin D, Dalay N . Mammaglobin and maspin transcripts in blood may reflect disease progression and the effect of therapy in breast cancer. Genet Mol Res. 2010; 9(1):97-106. DOI: 10.4238/vol9-1gmr649. View

11.

Mostert B, Sleijfer S, Foekens J, Gratama J . Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. Cancer Treat Rev. 2009; 35(5):463-74. DOI: 10.1016/j.ctrv.2009.03.004. View

12.

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

13.

Xenidis N, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, Stathopoulou A . Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol. 2006; 24(23):3756-62. DOI: 10.1200/JCO.2005.04.5948. View

14.

Tewes M, Aktas B, Welt A, Mueller S, Hauch S, Kimmig R . Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res Treat. 2008; 115(3):581-90. DOI: 10.1007/s10549-008-0143-x. View

15.

Bustin S . Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol. 2000; 25(2):169-93. DOI: 10.1677/jme.0.0250169. View

16.

Hayes D, Smerage J . Circulating tumor cells. Prog Mol Biol Transl Sci. 2010; 95:95-112. DOI: 10.1016/B978-0-12-385071-3.00005-8. View

17.

Ignatiadis M, Kallergi G, Ntoulia M, Perraki M, Apostolaki S, Kafousi M . Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin Cancer Res. 2008; 14(9):2593-600. DOI: 10.1158/1078-0432.CCR-07-4758. View

18.

Budd G, Cristofanilli M, Ellis M, Stopeck A, Borden E, Miller M . Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin Cancer Res. 2006; 12(21):6403-9. DOI: 10.1158/1078-0432.CCR-05-1769. View

19.

Pachmann K, Clement J, Schneider C, Willen B, Camara O, Pachmann U . Standardized quantification of circulating peripheral tumor cells from lung and breast cancer. Clin Chem Lab Med. 2005; 43(6):617-27. DOI: 10.1515/CCLM.2005.107. View

20.

Bustin S, Benes V, Garson J, Hellemans J, Huggett J, Kubista M . The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009; 55(4):611-22. DOI: 10.1373/clinchem.2008.112797. View